|
|
|
European Biopharmaceutical Review
|
| In June 2002 the US trial jury's decisions in a contract dispute between City of Hope National Medical Center (COH) and Genentech, over royalties payable to COH under a research agreement, led to orders that Genentech pay COH US$500 million in damages (US$300 million compensatory and US$200 million punitive). This article discusses the dispute and raises points for consideration when drafting biotechnology and pharmaceutical research agreements. Under an agreement dated 5th August 1976, Genentech funded the research of Dr Riggs and Dr Itakura at COH regarding synthesis of DNA strands coding for somatostatin and insulin. The 1976 agreement contained provisions that Genentech would own patents that arose but pay royalties to COH on exploitation of the technology by Genentech or third party licensees. The Riggs/Itakura research is said to have led to over 100 patents held by Genentech worldwide and has yielded commercially successful technology, including synthetic insulin products (1). There were only three products for which COH provided synthetic DNA to Genentech: insulin, growth hormone and somatostatin. There is no commercial product associated with the third. Over the years, Genentech has paid COH royalties on the first two totalling approximately US$300 million. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
BIO-Europe Spring® 2012 — 6th International Partnering Conference
19-21 March 2012, Amsterdam RAI Convention Center, Amsterdam, The Netherlands
BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.
More info >> |
|
 |
News and Press Releases |
 |
Prism Ideas and dMetrics Launch Pioneering Service Analysing Patient–Reported Action, Behaviours and Outcomes with Social Media
Prism Ideas, the multi-national medical marketing and drug development consultants, today announced its collaboration with dMetrics, experts in identifying decisions made by millions of patients online, to launch a pioneering analysis service to evaluate patient healthcare outcomes reported within social media. Combining expertise in language analytics and healthcare, the two companies are interrogating social media to determine patient actions and insights, profiling patient needs, symptoms and response to treatment.
More info >> |
|
|
